Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML

NCT02109627 is registered in ClinicalTrials.gov with C. Babis Andreadis as lead sponsor.

NCT NCT02109627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02109627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML
Lead sponsor
C. Babis Andreadis
Phase
Phase 1
Overall status
Terminated
Start date
May 1, 2015
Completion date
December 2, 2019
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, refractory acute myeloid leukemia, relapsed acute myeloid leukemia